Gene- and cell-based therapeutics for type I diabetes mellitus

Gene Therapy

Volumn 10, Issue 10, 2003, Pages 875-889

  Bottino, R ^a   Lemarchand, P ^b   Trucco, M ^a   Giannoukakis, N ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; CATALASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOKINASE; GLUCOSE TRANSPORTER 2; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; I KAPPA B ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE C DELTA; PROTEIN P40; PYRUVATE KINASE; SOMATOMEDIN C; STREPTOZOCIN; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PDX 1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN PRESENTING CELL; DENDRITIC CELL; DNA VECTOR; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; STEM CELL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CHEMOKINES; DIABETES MELLITUS, TYPE 1; GENE THERAPY; GENETIC VECTORS; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MODELS, ANIMAL; PROINSULIN; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 0038621437     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302015     Document Type: Review

References (275)

1. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5: 601-604.
2. Pietropaolo M et al. Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes. Diabetologia 2002; 45: 66-76.
3. Pietropaolo M, Trucco M. Major histocompatibility locus and other genes that determine risk of development of insulin-dependent Diabetes mellitus. In: LeRoith D, Taylor S, Olefsky JM (eds.), Diabetes Mellitus: A fundamental and Clinical Text. J.B. Lippincott & Co.; Philadelphia, PA, 2000, pp. 399-410.
4. Vafiadis P et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997; 15: 289-292.
5. Pugliese A et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997; 15: 293-297.
6. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 2002; 51: 1383-1390.
7. Mein CA et al. A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet 1998; 19: 297-300.
8. Concannon P et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1998; 19: 292-296.
9. Davies JL et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371: 130-136.
10. Oldstone MB. Molecular mimicry and immune-mediated diseases. Faseb J 1998; 12: 1255-1265.
11. von Herrath MG, Holz A, Homann D, Oldstone MB. Role of viruses in type I diabetes. Semin Immunol 1998; 10: 87-100.
12. Horwitz MS et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4: 781-785.
13. Karges W et al. Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes 1997; 46: 557-564.
14. Kaufman DL et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992; 89: 283-292.
15. Conrad B, Trucco M. Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1994; 10: 309-338.
16. Conrad B et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology Nature 1994; 371: 351-355.
17. Acerini CL et al. Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet. Diabet Med 1998; 15: 38-44.
18. Virtanen SM et al. Diet, cow's milk protein antibodies and the risk of IDDM in Finnish children. Childhood Diabetes in Finland Study Group. Diabetologia 1994; 37: 381-387.
19. Kostraba JN et al. Early infant diet and risk of IDDM in blacks and whites. A matched case-control study. Diabetes Care 1992; 15: 626-631.
20. Mandrup-Poulsen T et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic β-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993; 5: 185-191.
21. McDaniel ML et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 1996; 211: 24-32.
22. Arnush M et al. IL-1 produced and released endogenously within human islets inhibits β-cell function. J Clin Invest 1998; 102: 516-526.
23. Arnush M et al. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 1998; 160: 2684-2691.
24. Lacy PE. The intraislet macrophage and type I diabetes. Mt Sinai J Med 1994; 61: 170-174.
25. O'Brien BA, Fieldus WE, Field CJ, Finegood DT. Clearance of apoptotic β-cells is reduced in neonatal autoimmune diabetes-prone rats. Cell Death Differ 2002; 9: 457-464.
26. Trudeau JD et al. Neonatal β-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 2000; 49: 1-7.
27. Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S. Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 1997; 138: 1736-1741.
28. Giannoukakis N, Rudert WA, Robbins PD, Trucco M. Targeting autoimmune diabetes with gene therapy. Diabetes 1999; 48: 2107-2121.
29. Giannoukakis N, Thomson A, Robbins P. Gene therapy in transplantation. Gene Therapy 1999; 6: 1499-1511.
30. Bottino R, Trucco M, Balamurugan AN, Starzl TE. Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol 2002; 16: 457-474.
31. Sui G et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 5515-5520.
32. Kogure K et al. Targeted integration of foreign DNA into a defined locus on chromosome 19 in K562 cells using AAV-derived components. Int J Hematol 2001; 73, 469-475.
33. Pieroni L et al. Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. Virology 1998; 249: 249-259.
34. Ikeda Y et al. Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Therapy 2002; 9: 932-938.
35. O'Rourke JP et al. Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus-and human immunodeficiency virus type 1-derived lentivirus vectors. J Virol 2002; 76: 1510-1515.
36. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Therapy 1998; 5: 1481-1487.
37. Lotery AJ et al. Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum Gene Ther 2002; 13: 689-696.
38. Kelly PF et al. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96: 1206-1214.
39. Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 2000; 1: 31-38.
40. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
41. Britt LD, Scharp DW, Lacy PE, Slavin S. Transplantation of islet cells across major histocompatibility barriers after total lymphoid irradiation and infusion of allogeneic bone marrow cells. Diabetes 1982; 31(Suppl 4): 63-68.
42. Exner BG, Fowler K, Ildstad ST. Tolerance induction for islet transplantation. Ann Transplant 1997; 2: 77-80.
43. Rossini AA et al. Induction of immunological tolerance to islet allografts. Cell Transplant 1996; 5: 49-52.
44. Domenick MA, Ildstad ST. Impact of bone marrow transplantation on type I diabetes. World J Surg 2001; 25: 474-480.
45. Good RA, Verjee T. Historical and current perspectives on bone marrow transplantation for prevention and treatment of immunodeficiencies and autoimmunities. Biol Blood Marrow Transplant 2001; 7: 123-135.
46. Mathieu C, Bouillon R, Rutgeerts O, Waer M. Induction of mixed bone marrow chimerism as potential therapy for autoimmune (type I) diabetes: experience in the NOD model. Transplant Proc 1995; 27: 640-641.
47. Mathieu C, Vandeputte M, Bouillon R, Waer M. Protection against autoimmune diabetes by induction of mixed bone marrow chimerism. Transplant Proc 1993; 25: 1266-1267.
48. Li H, Kaufman CL, Ildstad ST. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery 1995; 118: 192-197; discussion 197-198.
49. Li H, Inverardi L, Ricordi C. Chimerism-induced remission of overt diabetes in nonobese diabetic mice. Transplant Proc 1999; 31: 640.
50. Zorina TD et al. Distinct characteristics and features of allogeneic chimerism in the NOD mouse model of autoimmune diabetes. Cell Transplant 2002; 11: 113-123.
51. Feili-Hariri M et al. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 1999; 48: 2300-2308.
52. Clare-Salzler MJ et al. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992; 90: 741-748.
53. Giannoukakis N et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-κB decoy oligodeoxyribonucleotides. Mol Ther 2000; 1: 430-437.
54. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002; 73: S19-22.
55. Lu L et al. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Therapy 1999; 6: 554-563.
56. Lu L et al. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-β, and CTLA4Ig). J Leukoc Biol 1999; 66: 293-296.
57. Thomson AW, Lu L. Dendritic cells as regulators of immune reactivity: implications for transplantation. Transplantation 1999; 68: 1-8.
58. Lee WC et al. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-β. Transplantation 1998; 66: 1810-1817.
59. Takayama T et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998; 66: 1567-1574.
60. Berney T et al. Transplantation of islets of Langerhans: new developments. Swiss Med Wkly 2001; 131: 671-680.
61. Boker A et al. Human islet transplantation: update. World J Surg 2001; 25: 481-486.
62. Berney T, Ricordi C. Islet cell transplantation: the future? Langenbecks Arch Surg 2000; 385: 373-378.
63. Berney T, Ricordi C. Islet transplantation. Cell Transplant 1999; 8: 461-464.
64. Rosenbloom AL et al. Therapeutic controversy: prevention and treatment of diabetes in children. J Clin Endocrinol Metab 2000; 85: 494-522.
65. Wilson K, Eisenbarth GS. Immunopathogenesis and immunotherapy of type 1 diabetes. Annu Rev Med 1990; 41: 497-508.
66. Papoz L et al. Probability of remission in individual in early adult insulin dependent diabetic patients. Results from the Cyclosporine Diabetes French Study Group. Diabetes Metab 1990; 16: 303-310.
67. Shimada A et al. T-cell insulitis found in anti-GAD65+ diabetes with residual β-cell function. A case report. Diabetes Care 1999; 22: 615-617.
68. Hamamoto Y et al. Recovery of function and mass of endogenous β-cells in streptozotocin-induced diabetic rats treated with islet transplantation. Biochem Biophys Res Commun 2001; 287: 104-109.
69. Rasmussen SB et al. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual β-cell function and mass in acutely diabetic BB rats. Horm Metab Res 2000; 32: 294-300.
70. Mayer A et al. The relationship between peripheral T-cell reactivity to insulin, clinical remissions and cytokine production in type 1 (insulin-dependent) diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 2419-2424.
71. Finegood DT, Weir GC, Bonner-Weir S. Prior streptozotocin treatment does not inhibit pancreas regeneration after 90% pancreatectomy in rats. Am J Physiol 1999; 276: E822-827.
72. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123-127.
73. Herold KC et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
74. Corbett JA, McDaniel ML. Intraislet release of interleukin 1 inhibits β-cell function by inducing β-cell expression of inducible nitric oxide synthase. J Exp Med 1995; 181: 559-568.
75. Heitmeier MR, Scarim AL, Corbett JA. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J Biol Chem 1997; 272: 13697-13704.
76. Scarim AL et al. Evidence for the presence of type I IL-1 receptors on β-cells of islets of Langerhans. Biochim Biophys Acta 1997; 1361: 313-320.
77. Faustman DL. Reversal of established autoimmune diabetes by in situ β-cell regeneration. Ann N Y Acad Sci 2002; 961: 40.
78. Mottram PL et al. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Transpl Immunol 2002; 10: 63-72.
79. French MB et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997; 46: 34-39.
80. Miyazaki T et al. Prevention of autoimmune insulitis in nonobese diabetic mice by expression of major histocompatibility complex class I Ld molecules. Proc Natl Acad Sci USA 1992; 89: 9519-9523.
81. Ridgway WM et al. Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T-cell response. J Exp Med 1998; 188: 2267-2275.
82. Ridgway WM, Fathman CG. The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetes. Clin Immunol Immunopathol 1998; 86: 3-10.
83. Johnson EA et al. Inhibition of autoimmune diabetes in nonobese diabetic mice by transgenic restoration of H2-E MHC class II expression: additive, but unequal, involvement of multiple APC subtypes. J Immunol 2001; 167: 2404-2410.
84. Gerling IC, Serreze DV, Christianson SW, Leiter EH. Intrathymic islet cell transplantation reduces β-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes 1992; 41: 1672-1676.
85. Jiang Y et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49.
86. Schwartz RE et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109: 1291-1302.
87. Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001; 938: 231-233; discussion 233-235.
88. Wagers AJ, Christensen JL, Weissman IL. Cell fate determination from stem cells. Gene Therapy 2002; 9: 606-612.
89. Leykin I, Nikolic B, Sykes M. Mixed bone marrow chimerism as a treatment for autoimmune diabetes. Transplant Proc 2001; 33: 120.
90. Steptoe RJ, Thomson AW. Dendritic cells and tolerance induction. Clin Exp Immunol 1996; 105: 397-402.
91. Takayama T et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998; 66: 1567-1574.
92. Lu L et al. Transduction of dendritic cells with adenoviral vectors encoding CTLA4-Ig markedly reduces their allostimulatory activity. Transplant Proc 1999; 31(1-2): 797.
93. Lee WC et al. Phenotype, function and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-β. Transplantation 1998; 66(12): 1810-1817.
94. Sharif S, Arreaza GA, Zucker P, Delovitch TL. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. Ann NY Acad Sci 2002; 958: 77-88.
95. Naumov YN et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001; 98: 13838-13843.
96. Sharif S, Delovitch TL. Regulation of immune responses by natural killer T cells. Arch Immunol Ther Exp (Warsz) 2001; 49: S23-S31.
97. Sharif S et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7: 1057-1062.
98. Hong S et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052-1056.
99. Pugliese A et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 2001; 107: 555-564.
100. Giannoukakis N et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-κB decoy oligodeoxyribonucleotides. Mol Ther 2000; 1: 430-437.
101. Shapiro AM et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
102. Ryan EA, Lakey JR, Shapiro AM. Clinical results after islet transplantation. J Investig Med 2001; 49: 559-562.
103. Shapiro AM, Ryan EA, Lakey JR. Pancreatic islet transplantation in the treatment of diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2001; 15: 241-264.
104. Ryan EA et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-719.
105. Bottino R et al. Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. Diabetes 2002; 51: 2561-2567.
106. Jaeschke H. Vascular oxidant stress and hepatic ischemia/reperfusion injury. Free Radic Res Commun 1991; 121-3: 737-743.
107. Jaeschke H. Reactive oxygen and ischemia/reperfusion injury of the liver. Chem Biol Interact 1991; 79: 115-136.
108. Paraskevas S et al. Cell loss in isolated human islets occurs by apoptosis. Pancreas 2000; 20: 270-276.
109. Rosenberg L, Wang R, Paraskevas S, Maysinger D. Structural and functional changes resulting from islet isolation lead to islet cell death. Surgery 1999; 126: 393-398.
110. Nagano H, Tilney NL. Chronic allograft failure: the clinical problem. Am J Med Sci 1997; 313: 305-309.
111. Bulkley GB. Free radical-mediated reperfusion injury: a selective review. Br J Cancer Suppl 1987; 8: 66-73.
112. Pileggi A et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 2001; 50: 1983-1991.
113. Tobiasch E, Gunther L, Bach FH. Heme oxygenase-1 protects pancreatic β-cells from apoptosis caused by various stimuli. J Investig Med 2001; 49, 566-571.
114. Contreras JL et al. Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement. Surgery 2001; 130: 166-174.
115. Contreras JL et al. Cytoprotection of pancreatic islets before and soon after transplantation by gene transfer of the anti-apoptotic Bcl-2 gene. Transplantation 2001; 71: 1015-1023.
116. Lortz S et al. Protection of insulin-producing RINm5F cells against cytokine-mediated toxicity through overexpression of antioxidant enzymes. Diabetes 2000; 49: 1123-1130.
117. Hotta M et al. Pancreatic β-cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 1998; 188: 1445-1451.
118. Embury J et al. Proteins linked to a protein transduction domain efficiently transduce pancreatic islets. Diabetes 2001; 50: 1706-1713.
119. Piganelli JD et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002; 51: 347-355.
120. Jaeschke H et al. Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol 1996; 139: 213-226.
121. Jaeschke H. Chemokines, neutrophils, and inflammatory liver injury. Shock 1996; 6: 403-404.
122. Dairaghi DJ et al. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem 1999; 274: 21569-21574.
123. Howard OM, Oppenheim JJ, Wang JM. Chemokines as molecular targets for therapeutic intervention. J Clin Immunol 1999; 19: 280-292.
124. Dong H, Woo SL. Hepatic insulin production for type 1 diabetes. Trends Endocrinol Metab 2001; 12: 441-446.
125. Dong H et al. Hepatic insulin expression improves glycemic control in type 1 diabetic rats. Diabetes Res Clin Pract 2001; 52: 153-163.
126. Thule PM, Liu JM. Regulated hepatic insulin gene therapy of STZ-diabetic rats. Gene Therapy 2000; 7: 1744-1752.
127. Mitanchez D et al. 5-Oxoprolinuria: a cause of neonatal metabolic acidosis. Acta Paediatr 2001; 90: 827-828.
128. Mitanchez D et al. Regulated expression of mature human insulin in the liver of transgenic mice. FEBS Lett 1998; 421: 285-289.
129. Mitanchez D, Doiron B, Chen R, Kahn A. Glucose-stimulated genes and prospects of gene therapy for type I diabetes. Endocrinol Rev 1997; 18: 520-540.
130. Flotte T et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes 2001; 50: 515-520.
131. Lee HC et al. Remission in models of type 1 diabetes by gene therapy using a single- chain insulin analogue. Nature 2000; 408: 483-488.
132. Yang YW, Kotin RM. Glucose-responsive gene delivery in pancreatic Islet cells via recombinant adeno-associated viral vectors. Pharm Res 2000; 17: 1056-1061.
133. Yang YW, Hsieh YC. Regulated secretion of proinsulin/insulin from human hepatoma cells transduced by recombinant adeno-associated virus. Biotechnol Appl Biochem 2001; 33: 133-140.
134. Bochan MR et al. Stable transduction of human pancreatic adenocarcinoma cells, rat fibroblasts, and bone marrow-derived stem cells with recombinant adeno-associated virus containing the rat preproinsulin II gene. Transplant Proc 1998; 30: 453-454.
135. Kasten-Jolly J et al. Reversal of hyperglycemia in diabetic NOD mice by human proinsulin gene therapy Transplant Proc 1997; 29: 2216-2218.
136. Bartlett RJ et al. Toward engineering skeletal muscle to release peptide hormone from the human pre-proinsulin gene. Transplant Proc 1998; 30: 451.
137. Simpson AM et al. Gene therapy of diabetes: glucose-stimulated insulin secretion in a human hepatoma cell line (HEP G2ins/g). Gene Therapy 1997; 4: 1202-1215.
138. Simonson GD, Groskreutz DJ, Gorman CM, MacDonald MJ. Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures. Hum Gene Ther 1996; 7: 71-78.
139. Vollenweider F, Irminger JC, Halban PA. Substrate specificity of proinsulin conversion in the constitutive pathway of transfected FAO (hepatoma) cells. Diabetologia 1993; 36: 1322-1325.
140. Vollenweider F et al. Processing of proinsulin by transfected hepatoma (FAO) cells. J Biol Chem 1992; 267: 14629-14636.
141. Groskreutz DJ, Sliwkowski MX, Gorman CM. Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem 1994; 269: 6241-6245.
142. Thule PM, Liu J, Phillips LS. Glucose regulated production of human insulin in rat hepatocytes. Gene Therapy 2000; 7: 205-214.
143. Chen R, Meseck ML, Woo SL. Auto-regulated hepatic insulin gene expression in type 1 diabetic rats. Mol Ther 2001; 3: 584-590.
144. Chen R, Meseck M, McEvoy RC, Woo SL. Glucose-stimulated and self-limiting insulin production by glucose 6-phosphatase promoter driven insulin expression in hepatoma cells. Gene Therapy 2000; 7: 1802-1809.
145. Iynedjian PB et al. Transcriptional induction of glucokinase gene by insulin in cultured liver cells and its repression by the glucagon-cAMP system. J Biol Chem 1989; 264: 21824-21829.
146. Iynedjian PB et al. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc Natl Acad Sci USA 1989; 86: 7838-7842.
147. Liu JS et al. Cyclic AMP induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription is mediated by multiple promoter elements. J Biol Chem 1991; 266: 19095-19102.
148. Klemm DJ et al. In vitro analysis of promoter elements regulating transcription of the phosphoenolpyruvate carboxykinase (GTP) gene. Mol Cell Biol 1990; 10: 480-485.
149. Lipes MA et al. Insulin-secreting non-islet cells are resistant to autoimmune destruction. Proc Natl Acad Sci USA 1996; 93: 8595-8600.
150. Lipes MA, Davalli AM, Cooper EM. Genetic engineering of insulin expression in nonislet cells: implications for β-cell replacement therapy for insulin-dependent diabetes mellitus. Acta Diabetol 1997; 34: 2-5.
151. Cheung AT et al. Glucose-dependent insulin release from genetically engineered K cells. Science 2000; 290: 1959-1962.
152. Cornelius JG, Tchernev V, Kao KJ, Peck AB. In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas. Horm Metab Res 1997; 29: 271-277.
153. Beattie GM et al. Regulation of proliferation and differentiation of human fetal pancreatic islet cells by extracellular matrix, hepatocyte growth factor, and cell-cell contact. Diabetes 1996; 45: 1223-1228.
154. Beattie GM, Lopez AD, Hayek A. In vivo maturation and growth potential of human fetal pancreases: fresh versus cultured tissue. Transplant Proc 1995; 27: 3343.
155. Beattie GM, Hayek A. Outcome of human fetal pancreatic transplants according to implantation site. Transplant Proc 1994; 26, 3299.
156. Beattie GM, Cirulli V, Lopez AD, Hayek A. Ex vivo expansion of human pancreatic endocrine cells. J Clin Endocrinol Metab 1997; 82: 1852-1856.
157. Lumelsky N et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001; 292: 1389-1394.
158. McKay R. Stem cells-hype and hope. Nature 2000; 406: 361-364.
159. Colman A, Kind A. Therapeutic cloning: concepts and practicalities. Trends Biotechnol 2000; 18: 192-196.
160. Kind A, Colman A. Therapeutic cloning: needs and prospects. Semin Cell Dev Biol 1999; 10: 279-286.
161. Lanza RP, Cibelli JB, West MD. Human therapeutic cloning. Nat Med 1999; 5: 975-977.
162. D'Ambra R et al. Regulation of insulin secretion from β-cell lines derived from transgenic mice insulinomas resembles that of normal β-cells. Endocrinology 1990; 126: 2815-2822.
163. Efrat S et al. Conditional transformation of a pancreatic β-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci USA 1995; 92: 3576-3580.
164. Efrat S. Cell-based therapy for insulin-dependent diabetes mellitus. Eur J Endocrinol 1998; 138: 129-133.
165. Fleischer N et al. Functional analysis of a conditionally transformed pancreatic β-cell line. Diabetes 1998; 47: 1419-1425.
166. Hayek A et al. Growth factor/matrix-induced proliferation of human adult β-cells. Diabetes 1995; 44: 1458-1460.
167. Otonkoski T et al. Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. Diabetes 1994; 43: 947-953.
168. Otonkoski T et al. A role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced pancreatic β-cell growth. Endocrinology 1996; 137: 3131-3139.
169. Levine F, Leibowitz G. Towards gene therapy of diabetes mellitus. Mol Med Today 1999; 5: 165-171.
170. Beattie GM et al. Sustained proliferation of PDX-1+ cells derived from human islets. Diabetes 1999; 48: 1013-1019.
171. Habener JF, Stoffers DA. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Assoc Am Physicians 1998; 110: 12-21.
172. Madsen OD et al. Transcription factors contributing to the pancreatic β-cell phenotype. Horm Metab Res 1997; 29: 265-270.
173. Sander M, German MS. The β-cell transcription factors and development of the pancreas. J Mol Med 1997; 75: 327-340.
174. Ferber S et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 2000; 6: 568-572.
175. Wu KL et al. Hepatocyte nuclear factor 3β is involved in pancreatic β-cell-specific transcription of the pdx-1 gene. Mol Cell Biol 1997; 17: 6002-6013.
176. Oster A et al. Rat endocrine pancreatic development in relation to two homeobox gene products (Pdx-1 and Nkx 6.1). J Histochem Cytochem 1998; 46: 707-715.
177. Hill DJ, Hogg J. Growth factor control of pancreatic B cell hyperplasia. Baillieres Clin Endocrinol Metab 1991; 5: 689-698.
178. Ilieva A et al. Pancreatic islet cell survival following islet isolation: the role of cellular interactions in the pancreas. J Endocrinol 1999; 161: 357-364.
179. Miettinen PJ, Otonkoski T, Voutilainen R. Insulin-like growth factor-II and transforming growth factor-α in developing human fetal pancreatic islets. J Endocrinol 1993; 138: 127-136.
180. Petrik J, Arany E, McDonald TJ, Hill DJ. Apoptosis in the pancreatic islet cells of the neonatal rat is associated with a reduced expression of insulin-like growth factor II that may act as a survival factor. Endocrinology 1998; 139: 2994-3004.
181. Petrik J et al. Overexpression of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell hyperplasia. Endocrinology 1999; 140: 2353-2363.
182. Markoff E, Beattie GM, Hayek A, Lewis UJ. Effects of prolactin and glycosylated prolactin on (pro)insulin synthesis and insulin release from cultured rat pancreatic islets. Pancreas 1990; 5: 99-103.
183. Kawai M, Kishi K. In vitro studies of the stimulation of insulin secretion and B-cell proliferation by rat placental lactogen-II during pregnancy in rats. J Reprod Fertil 1997; 109: 145-152.
184. Billestrup N, Nielsen JH. The stimulatory effect of growth hormone, prolactin, and placental lactogen on β-cell proliferation is not mediated by insulin-like growth factor-I. Endocrinology 1991; 129: 883-888.
185. Vasavada RC et al. Overexpression of parathyroid hormone-related protein in the pancreatic islets of transgenic mice causes islet hyperplasia, hyperinsulinemia, and hypoglycemia. J Biol Chem 1996; 271: 1200-1208.
186. Porter SE et al. Progressive pancreatic islet hyperplasia in the islet-targeted, parathyroid hormone-related protein-overexpressing mouse. Endocrinology 1998; 139: 3743-3751.
187. Wang RN, Rehfeld JF, Nielsen FC, Kloppel G. Expression of gastrin and transforming growth factor-α during duct to islet cell differentiation in the pancreas of duct-ligated adult rats. Diabetologia 1997; 40: 887-893.
188. Miettinen PJ. Transforming growth factor-α and epidermal growth factor expression in human fetal gastrointestinal tract. Pediatr Res 1993; 33: 481-486.
189. Baeza N, Hart A, Ahlgren U, Edlund H. Insulin promoter factor-1 controls several aspects of β-cell identity. Diabetes 2001; 50(Suppl 1): S36.
190. Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse β-cells leads to diabetes. Nature 2000; 408: 864-868.
191. Yamaoka T, Itakura M. Development of pancreatic islets (review). Int J Mol Med 1999; 3: 247-261.
192. Mally MI, Otonkoski T, Lopez AD, Hayek A. Developmental gene expression in the human fetal pancreas. Pediatr Res 1994; 36: 537-544.
193. Unno M et al. Islet β-cell regeneration and reg genes. Adv Exp Med Biol 1992; 321: 61-66.
194. Zenilman ME, Chen J, Danesh B, Zheng QH. Characteristics of rat pancreatic regenerating protein. Surgery 1998; 124: 855-863.
195. Zenilman ME, Chen J, Magnuson TH. Effect of reg protein on rat pancreatic ductal cells. Pancreas 1998; 17: 256-261.
196. Bone AJ, Banister SH, Zhang S. The REG gene and islet cell repair and renewal in type 1 diabetes. Adv Exp Med Biol 1997; 426: 321-327.
197. Vinik A et al. Induction of pancreatic islet neogenesis. Horm Metab Res 1997; 29: 278-293.
198. Rafaeloff R et al. Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. J Clin Invest 1997; 99: 2100-2109.
199. Bonner-Weir S et al. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 2000; 97: 7999-8004.
200. Dai Y et al. Targeted disruption of the α 1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002; 20: 251-255.
201. Koike C et al. Molecular basis of evolutionary loss of the α 1,3-galactosyltransferase gene in higher primates. J Biol Chem 2002; 277: 10114-10120.
202. Gainer AL et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998; 66: 194-199.
203. Gainer AL et al. Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival. Transplantation 1997; 63: 1017-1021.
204. Welsh N, Oberg C, Hellerstrom C, Welsh M. Liposome mediated in vitro transfection of pancreatic islet cells. Biomed Biochim Acta 1990; 49: 1157-1164.
205. Benhamou PY et al. Standardization of procedure for efficient
206. Smith DK et al. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent β-cell destruction in diabetic NOD mice. Transplantation 1997; 64: 1040-1049.
207. Yasuda H et al. Local expression of immunoregulatory IL-12p4O gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 1998; 102: 1807-1814.
208. Benhamou PY et al. Decreased alloreactivity to human islets secreting recombinant viral interleukin 10. Transplantation 1996; 62: 1306-1312.
209. Judge TA et al. Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation 1998; 66: 426-434.
210. von Herrath MG, Efrat S, Oldstone MB, Horwitz MS. Expression of adenoviral E3 transgenes in β-cells prevents autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 9808-9813.
211. Weber M et al. Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. I Surg Res 1997; 69: 23-32.
212. Csete ME et al. Efficient gene transfer to pancreatic islets mediated by adenoviral vectors. Transplantation 1995; 59: 263-268.
213. Raper SE, DeMatteo RP. Adenovirus-mediated in vivo gene transfer and expression in normal rat pancreas. Pancreas 1996; 12: 401-410.
214. Saldeen J et al. Efficient gene transfer to dispersed human pancreatic islet cells in vitro using adenovirus-polylysine/DNA complexes or polycationic liposomes. Diabetes 1996; 45: 1197-1203.
215. Giannoukakis N et al. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1β-induced β-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999; 48: 1730-1736.
216. Grey ST et al. A20 inhibits cytokine-induced apoptosis and nuclear factor κ B-dependent gene activation in islets. J Exp Med 1999; 190: 1135-1146.
217. Muruve DA, Manfro RC, Strom TB, Libermann TA. Ex vivo adenovirus-mediated gene delivery leads to long-term expression in pancreatic islet transplants. Transplantation 1997; 64: 542-546.
218. Becker TC et al. Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. Enhancement of glucose metabolism and insulin secretion at basal but not stimulatory glucose levels. J Biol Chem 1994; 269: 21234-21238.
219. Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an IκB repressor. J Biol Chem, 2000; 275(47): 36509-36513.
220. Kapturczak M et al. Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector. Mol Ther 2002; 5: 154-160.
221. Shifrin AL et al. Adenoviral vector-mediated insulin gene transfer in the mouse pancreas corrects streptozotocin-induced hyperglycemia. Gene Therapy 2001; 8: 1480-1489.
222. Alexander AM et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51: 356-365.
223. Uchikoshi F et al. Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat. Diabetes 1999; 48: 652-657.
224. Moriscot C et al. Contribution of adenoviral-mediated superoxide dismutase gene transfer to the reduction in nitric oxide-induced cytotoxicity on human islets and INS-1 insulin-secreting cells. Diabetologia 2000; 43: 625-631.
225. Guo Z et al. Efficient gene transfer and expression in islets by an adenoviral vector that lacks all viral genes. Cell Transplant 1999; 8: 661-671.
226. Giannoukakis N et al. Prevention of β-cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Therapy 2000; 7: 2015-2022.
227. Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an Iκ B repressor. J Biol Chem 2000; 275: 36509-36513.
228. Giannoukakis N et al. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1β-induced β-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999; 48: 1730-1736.
229. Leibowitz G et al. Gene transfer to human pancreatic endocrine cells using viral vectors. Diabetes 1999; 48: 745-753.
230. Gallichan WS et al. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Ham Gene Ther 1998; 9: 2717-2726.
231. Ju Q et al. Transduction of non-dividing adult human pancreatic β-cells by an integrating lentiviral vector. Diabetologia 1998; 41: 736-739.
232. Giannoukakis N et al. Infection of intact human islets by a lentiviral vector. Gene Therapy 1999; 6: 1545-1551.
233. Liu Y et al. Expression of the bcl-2 gene from a defective HSV-1 amplicon vector protects pancreatic β-cells from apoptosis. Hum Gene Ther 1996; 7: 1719-1726.
234. Rabinovitch A et al. Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects β-cells from cytokine-induced destruction. Diabetes 1999; 48: 1223-1229.
235. Mi Z, Mai J, Lu X, Robbins PD. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol Ther 2000; 2: 339-347.
236. Dupraz P et al. Lentivirus-mediated Bcl-2 expression in βTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Therapy 1999; 6: 1160-1169.
237. Zhou YP et al. Overexpression of Bcl-x(L) in β-cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab 2000; 278: E340-351.
238. Ye J, Laychock SG. A protective role for heme oxygenase expression in pancreatic islets exposed to interleukin-1β. Endocrinology 1998; 139: 4155-4163.
239. Carpenter L, Cordery D, Biden TJ. Inhibition of protein kinase Cδ protects rat INS-1 cells against interleukin-1β and streptozotocin-induced apoptosis. Diabetes 2002; 51: 317-324.
240. Dupraz P et al. Dominant negative MyD88 proteins inhibit interleukin-1β/interferon-γ-mediated induction of nuclear factor κ B-dependent nitrite production and apoptosis in β-cells. J Biol Chem 2000; 275: 37672-37678.
241. Burkart V et al. Natural resistance of human β-cells toward nitric oxide is mediated by heat shock protein 70. J Biol Chem 2000; 275: 19521-19528.
242. Xu B, Moritz JT, Epstein PN. Overexpression of catalase provides partial protection to transgenic mouse β-cells. Free Radic Biol Med 1999; 27: 830-837.
243. Benhamou PY et al. Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets. Diabetologia 1998; 41: 1093-1100.
244. Hohmeier HE et al. Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1β-induced cytotoxicity and reduces nitric oxide production. J Clin Invest 1998; 101: 1811-1820.
245. Gallichan WS et al. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998; 9: 2717-2726.
246. Deng S et al. IL-10 and TGF-β gene transfer to rodent islets: effect on xenogeneic islet graft survival in naive and B-cell-deficient mice. Transplant Proc 1997; 29: 2207-2208.
247. Hao W, Palmer JP. Recombinant human transforming growth factor β does not inhibit the effects of interleukin-1β on pancreatic islet cells. J Interferon Cytokine Res 1995; 15: 1075-1081.
248. Kang SM et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738-743.
249. Mathieu C, Casteels K, Bouillon R, Waer M. Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved. J Immunol 1997; 158: 1453-1457.
250. Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. Ann Transplant 2001; 6: 43-45.
251. Seung E et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000; 95: 2175-2182.
252. Li H, Colson YL, Ildstad ST. Mixed allogeneic chimerism achieved by lethal and nonlethal conditioning approaches induces donor-specific tolerance to simultaneous islet allografts. Transplantation 1995; 60: 523-529.
253. Li H et al. Mixed xenogeneic chimerism (mouse+rat → mouse) to induce donor-specific tolerance to sequential or simultaneous islet xenografts. Transplantation 1994; 57: 592-598.
254. Rossini AA et al. Islet cell transplantation tolerance. Transplantation 2001; 72: S43-46.
255. Ali A et al. Major histocompatibility complex class I peptide-pulsed host dendritic cells induce antigen-specific acquired thymic tolerance to islet cells. Transplantation 2000; 69: 221-226.
256. Bertry-Coussot L et al. Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway J Immunol 2002; 168: 3641-3648.
257. Georgiou HM, Brady JL, Silva A, Lew AM. Genetic modification of an islet tumor cell line inhibits its rejection. Transplant Proc 1997; 29: 1032-1033.
258. Lew AM et al. Secretion of CTLA4Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen. Transplantation 1996; 62: 83-89.
259. Weber CJ et al. CTLA4-Ig prolongs survival of microencapsulated rabbit islet xenografts in spontaneously diabetic Nod mice. Transplant Proc 1996; 28: 821-823.
260. Brady JL, Lew AM. Additive efficacy of CTLA4Ig and OX40Ig secreted by genetically modified grafts. Transplantation 2000; 69: 724-730.
261. Sutherland RM et al. Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allografts. Transplantation 2000; 69: 1806-1812.
262. Goudy K et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98: 13913-13918.
263. Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol Ther 2001; 4: 313-316.
264. Koh JJ et al. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Therapy 2000; 7: 2099-2104.
265. Yang Z et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168: 6479-6485.
266. Zipris D, Karnieli E. A single treatment with IL-4 via retrovirally transduced lymphocytes partially protects against diabetes in BioBreeding (BB) rats. Jop 2002; 3: 76-82.
267. Chang Y, Prud'homme GJ. Intramuscular administration of expression plasmids encoding interferon-γ receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J Gene Med 1999; 1: 415-423.
268. Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-γ receptor/IgG1 fusion protein. Gene Therapy 1999; 6: 771-777.
269. Piccirillo CA, Chang Y, Prud'homme GJ. TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161: 3950-3956.
270. Balasa B et al. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin Immunol 2001; 99: 241-252.
271. Efrat S et al. Adenovirus early region 3(E3) immunomodulatory genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes 2001; 50: 980-984.
272. Weiner HL et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809-837.
273. Polanski M, Melican NS, Zhang J, Weiner HL. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997; 10: 339-346.
274. Bergerot I et al. Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 1999; 48: 1720-1729.
275. Prud'homme GJ, Chang Y, Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther 2002; 13: 395-406.